Latest News about AZNCF
Recent news which mentions AZNCF
From Benzinga
From Benzinga
Drugmakers, Health Authorities Discarding Several Million COVID-19 Vaccine Doses: Report
July 06, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study
June 30, 2022
From Benzinga
From Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
June 27, 2022
From Benzinga
From Benzinga
From Benzinga
Why Mereo BioPharma Shares Are Jumping Today
June 17, 2022
From Benzinga
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
June 06, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
May 05, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
April 27, 2022
From Benzinga
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
April 25, 2022
From Benzinga
World's Largest Vaccine Manufacturer Stops Making COVID-19 Vaccines As 200M Doses Pile-Up: Bloomberg
April 22, 2022
From Benzinga
From Benzinga
AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals
April 21, 2022
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free